who made tirzepatide Novo weight-loss drug may preserve lean body mass better than Lilly's, study finds Tirzepatide vs. Semaglutide for Weight

Q., Majid, A., Fatima, H., Ahmed, M., & Kim, S

Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial

tirzepatide is technically a dual GIP and GLP-1 receptor agonist) after a Stage I to III obesity-related cancer diagnosis, comparing them with patients who started a DPP-4 inhibitor instead

Presented for research literature review only Pace S et al

For short-half-life peptides that fail the oral feasibility test, long-acting injectable formulations may be the most realistic pathway to reduced treatment burden (Table 4)